Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Slides:

Advertisements

Similar presentations

How to manage suspected cancer

Advertisements

Osteoporosis therapy: an example of putting evidence- based medicine into clinical practice by D.J. Hosking, P. Geusens, and R. Rizzoli QJM Volume 98(6):

Emergencies in hereditary haemorrhagic telangiectasia by M. Gallitelli, G. Pasculli, T. Fiore, A. Carella, and C. Sabbà QJM Volume 99(1):15-22 December.

Breast Ovarian Hereditary Breast & Ovarian Cancer Knowing one’s family medical history can be life-saving.

Godoy & Godoy technique of cervical stimulation in the reduction of edema of the face after cancer treatment by José Maria Pereira de Godoy, Maria de Fátima.

Cancer cachexia by J.N. Gordon, S.R. Green, and P.M. Goggin QJM Volume 98(11): October 17, 2005 © The Author Published by Oxford University.

Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis by Tuula A. Paajanen, Niku K.J. Oksala,

Lower incisor intrusion with intraoral transosseous stainless steel wire anchorage in rabbits by Jian-chao Wu, Ji-na Huang, and Xin-ping Lin Eur J Orthod.

Disorders of cognitive and affective development in cerebellar malformations by Alessandro Tavano, Rita Grasso, Chiara Gagliardi, Fabio Triulzi, Nereo.

From: A Regularist Approach to Mechanistic Type-Level Explanation

From: Global Banking: Recent Developments and Insights from Research*

Figure 2. Quality of life (QOL) scores for functional scale items

Figure 3. Day 2 cell symmetry

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 2. CONSORT flow diagram.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1 Individual Lifted from Group Photograph

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1 (A) Chest computed tomography scans of the patient

Figure 2. (A) Sézary syndrome patient before treatment

Figure 1 Overview of the IMPACT Analysis Pipeline

Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

From: Where do we go from here

From: Estimating the Location of World Wheat Price Discovery

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1. Scattergram of serum CA-125 levels in 775 consecutive patients who had been diagnosed with gynecologic disease by laparotomy or laparoscopy.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

FIG. 4. Working lifetime combined risk from fatal heart disease and lung cancer based on Hong Kong exposure to secondhand tobacco smoke and both US and.

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

Figure 1. HR (95% CI) of death from dementia associated with weight or BMI in middle age and in old age. From: Adiposity in middle and old age and risk.

Progesterone receptor nuclear morphology patterns in breast cancer.

The decision tree with the two alternatives.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Take home figure The protective role of CNP/NPR-B/NPRC.

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Specific Tumor Suppressor Genes

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.

BRCA1 and BRCA2 Testing: Weighing the Demand against the Benefits

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Figure 1. A summary of phase 3 trials for previously untreated advanced/metastatic NSCLC. AEs, adverse events; Beva, ... Figure 1. A summary of phase 3.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Figure 1. CONSORT diagram.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Figure 1. Heterogeneous HER2 immunostaining in two gastric cancer samples classified as HER2 3+. (A) Complete ... Figure 1. Heterogeneous HER2 immunostaining.

Presentation transcript:

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA2 mutation carriers. Both diagrams from Antoniou et al. 2003 [3] From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi:10.1093/annonc/mdq365 Ann Oncol | © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Figure 2. A high-risk family. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi:10.1093/annonc/mdq365 Ann Oncol | © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Figure 3. The normal cells of BRCA carriers carry one normal copy and one mutated copy of the BRCA gene. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi:10.1093/annonc/mdq365 Ann Oncol | © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Figure 4. Tumour cells in BRCA carriers have no normal copies of the BRCA gene, and are therefore BRCA deficient. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi:10.1093/annonc/mdq365 Ann Oncol | © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Figure 5. The multi-step model of carcinogenesis allows for loss of tumour suppressor genes playing an important role in the process. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi:10.1093/annonc/mdq365 Ann Oncol | © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Figure 6. Initial Clinical Positioning of the BCtect® test in the UK private sector as agreed by the BCtect® UK strategy group. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi:10.1093/annonc/mdq365 Ann Oncol | © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org